Drug intelligence / Profile preview

clozapine + modafinil

Development stage: Discontinued
Lead developer: Sandoz
Modality: Small Molecules
Administration: Oral

Overview

The combination of clozapine and modafinil represents a drug interaction rather than a single pharmaceutical product. This combination has been studied in clinical settings, particularly for addressing clozapine-induced sedation in schizophrenia patients. Clozapine is an atypical antipsychotic medication primarily used to treat schizophrenia, while modafinil is a wakefulness-promoting agent. When combined, modafinil may increase blood levels of clozapine through the inhibition of cytochrome P450 2C19, potentially leading to clozapine toxicity.

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)CYP2C19 (Cytochrome P450 2C19)DAT (Dopamine plasma membrane transport protein)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on clozapine + modafinil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clozapine + modafinil.

Explore the full profile